Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation

G. P. Berezuk, S. W. Schondelmeyer, J. J. Seidenfeld, W. N. Jones, J Lyle Bootman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The clinical effectiveness of albuterol, isoetharine, and metaproterenol administered by aerosol inhalation at manufacturer-recommended doses was compared. A double-blind, placebo-controlled, crossover comparison of albuterol 280 μg, isoetharine 680 μg, and metaproterenol 1300 μg was conducted in 10 adult men with reversible, chronic pulmonary obstruction. FEV 1 (force expiratory volume at one second), FEF 25-75 (forced expiratory flow rate from 25 to 75% of vital capacity), and FVC (forced vital capacity) were determined periodically for six hours after drug administration. Bronchodilator effects, adverse effects, and cost of treatments were compared. Theophylline therapy was unaltered during the study, and serum theophylline concentration was determined periodically to control for its effect on pulmonary function. Serum theophylline concentration was not used as a covariate since it resulted in minimal change in the pulmonary-function measures. The mean maximum percent change from baseline for FEV 1 for each drug was superior to placebo; there were no differences among drugs. Comparing area under the curve of mean percent change in FEV 1 versus time, albuterol and metaproterenol produced changes that were greater than placebo but not different from each other or isoetharine. For FEF 25-75 and FVC, albuterol and metaproterenol, respectively, were superior. No pattern of adverse effects was identifiable among the four treatments. The average wholesale cost of albuterol products was approximately 1.7 times the cost of metaproterenol products. Under the conditions of this study, metaproterenol was superior to isoetharine and therapeutically equivalent to and less expensive than albuterol.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalClinical Pharmacy
Volume2
Issue number2
StatePublished - 1983
Externally publishedYes

Fingerprint

Isoetharine
Metaproterenol
Albuterol
Aerosols
Inhalation
Vital Capacity
Theophylline
Placebos
Lung
Forced Expiratory Flow Rates
Pharmaceutical Preparations
Costs and Cost Analysis
Bronchodilator Agents
Serum
Health Care Costs
Area Under Curve

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Berezuk, G. P., Schondelmeyer, S. W., Seidenfeld, J. J., Jones, W. N., & Bootman, J. L. (1983). Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation. Clinical Pharmacy, 2(2), 129-134.

Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation. / Berezuk, G. P.; Schondelmeyer, S. W.; Seidenfeld, J. J.; Jones, W. N.; Bootman, J Lyle.

In: Clinical Pharmacy, Vol. 2, No. 2, 1983, p. 129-134.

Research output: Contribution to journalArticle

Berezuk, GP, Schondelmeyer, SW, Seidenfeld, JJ, Jones, WN & Bootman, JL 1983, 'Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation', Clinical Pharmacy, vol. 2, no. 2, pp. 129-134.
Berezuk, G. P. ; Schondelmeyer, S. W. ; Seidenfeld, J. J. ; Jones, W. N. ; Bootman, J Lyle. / Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation. In: Clinical Pharmacy. 1983 ; Vol. 2, No. 2. pp. 129-134.
@article{b6c50b8a4bd5480c8f041b1bc91a3d0e,
title = "Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation",
abstract = "The clinical effectiveness of albuterol, isoetharine, and metaproterenol administered by aerosol inhalation at manufacturer-recommended doses was compared. A double-blind, placebo-controlled, crossover comparison of albuterol 280 μg, isoetharine 680 μg, and metaproterenol 1300 μg was conducted in 10 adult men with reversible, chronic pulmonary obstruction. FEV 1 (force expiratory volume at one second), FEF 25-75 (forced expiratory flow rate from 25 to 75{\%} of vital capacity), and FVC (forced vital capacity) were determined periodically for six hours after drug administration. Bronchodilator effects, adverse effects, and cost of treatments were compared. Theophylline therapy was unaltered during the study, and serum theophylline concentration was determined periodically to control for its effect on pulmonary function. Serum theophylline concentration was not used as a covariate since it resulted in minimal change in the pulmonary-function measures. The mean maximum percent change from baseline for FEV 1 for each drug was superior to placebo; there were no differences among drugs. Comparing area under the curve of mean percent change in FEV 1 versus time, albuterol and metaproterenol produced changes that were greater than placebo but not different from each other or isoetharine. For FEF 25-75 and FVC, albuterol and metaproterenol, respectively, were superior. No pattern of adverse effects was identifiable among the four treatments. The average wholesale cost of albuterol products was approximately 1.7 times the cost of metaproterenol products. Under the conditions of this study, metaproterenol was superior to isoetharine and therapeutically equivalent to and less expensive than albuterol.",
author = "Berezuk, {G. P.} and Schondelmeyer, {S. W.} and Seidenfeld, {J. J.} and Jones, {W. N.} and Bootman, {J Lyle}",
year = "1983",
language = "English (US)",
volume = "2",
pages = "129--134",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "2",

}

TY - JOUR

T1 - Clinical comparison of albuterol, isoetharine, and metaproterenol given by aerosol inhalation

AU - Berezuk, G. P.

AU - Schondelmeyer, S. W.

AU - Seidenfeld, J. J.

AU - Jones, W. N.

AU - Bootman, J Lyle

PY - 1983

Y1 - 1983

N2 - The clinical effectiveness of albuterol, isoetharine, and metaproterenol administered by aerosol inhalation at manufacturer-recommended doses was compared. A double-blind, placebo-controlled, crossover comparison of albuterol 280 μg, isoetharine 680 μg, and metaproterenol 1300 μg was conducted in 10 adult men with reversible, chronic pulmonary obstruction. FEV 1 (force expiratory volume at one second), FEF 25-75 (forced expiratory flow rate from 25 to 75% of vital capacity), and FVC (forced vital capacity) were determined periodically for six hours after drug administration. Bronchodilator effects, adverse effects, and cost of treatments were compared. Theophylline therapy was unaltered during the study, and serum theophylline concentration was determined periodically to control for its effect on pulmonary function. Serum theophylline concentration was not used as a covariate since it resulted in minimal change in the pulmonary-function measures. The mean maximum percent change from baseline for FEV 1 for each drug was superior to placebo; there were no differences among drugs. Comparing area under the curve of mean percent change in FEV 1 versus time, albuterol and metaproterenol produced changes that were greater than placebo but not different from each other or isoetharine. For FEF 25-75 and FVC, albuterol and metaproterenol, respectively, were superior. No pattern of adverse effects was identifiable among the four treatments. The average wholesale cost of albuterol products was approximately 1.7 times the cost of metaproterenol products. Under the conditions of this study, metaproterenol was superior to isoetharine and therapeutically equivalent to and less expensive than albuterol.

AB - The clinical effectiveness of albuterol, isoetharine, and metaproterenol administered by aerosol inhalation at manufacturer-recommended doses was compared. A double-blind, placebo-controlled, crossover comparison of albuterol 280 μg, isoetharine 680 μg, and metaproterenol 1300 μg was conducted in 10 adult men with reversible, chronic pulmonary obstruction. FEV 1 (force expiratory volume at one second), FEF 25-75 (forced expiratory flow rate from 25 to 75% of vital capacity), and FVC (forced vital capacity) were determined periodically for six hours after drug administration. Bronchodilator effects, adverse effects, and cost of treatments were compared. Theophylline therapy was unaltered during the study, and serum theophylline concentration was determined periodically to control for its effect on pulmonary function. Serum theophylline concentration was not used as a covariate since it resulted in minimal change in the pulmonary-function measures. The mean maximum percent change from baseline for FEV 1 for each drug was superior to placebo; there were no differences among drugs. Comparing area under the curve of mean percent change in FEV 1 versus time, albuterol and metaproterenol produced changes that were greater than placebo but not different from each other or isoetharine. For FEF 25-75 and FVC, albuterol and metaproterenol, respectively, were superior. No pattern of adverse effects was identifiable among the four treatments. The average wholesale cost of albuterol products was approximately 1.7 times the cost of metaproterenol products. Under the conditions of this study, metaproterenol was superior to isoetharine and therapeutically equivalent to and less expensive than albuterol.

UR - http://www.scopus.com/inward/record.url?scp=0020679223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020679223&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 129

EP - 134

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 2

ER -